Your browser doesn't support javascript.
loading
Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.
Shinjoh, Masayoshi; Yaginuma, Mizuki; Yamaguchi, Yoshio; Tamura, Kazuyo; Furuichi, Munehiro; Tsumura, Yuki; Itaki, Ryo; Iqbal, Asef; Maeda, Naonori; Narabayashi, Atsushi; Kamei, Akinobu; Shibata, Akimichi; Yamada, Go; Nishida, Mitsuhiro; Kenichiro, Tsunematsu; Chiga, Michiko; Shimoyamada, Motoko; Yoshida, Makoto; Fukushima, Naoya; Nakata, Yuji; Fukushima, Hiroyuki; Kawakami, Chiharu; Narumi, Satoshi; Sugaya, Norio.
Afiliación
  • Shinjoh M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Division of Infectious Diseases and Infection Control, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: m-shinjo@keio.jp.
  • Yaginuma M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
  • Yamaguchi Y; Department of Clinical Research, Department of Infection and Allergy, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomaturi, Utsunomiya-City, Tochigi 320-8580, Japan.
  • Tamura K; Department of Pediatrics, Nippon Koukan Hospital, 1-2-1 Koukan-dori, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0852, Japan.
  • Furuichi M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
  • Tsumura Y; Department of Pediatrics, Keiyu Hospital, 3-7-3 Minatomirai Nishi-ku, Yokohama-shi, Kanagawa 220-8521, Japan.
  • Itaki R; Department of Pediatrics, Tokyo Metropolitan Otsuka Hospital, 2-8-1 Minamiotsuka, Toshima-ku, Tokyo 170-8476, Japan.
  • Iqbal A; Department of Pediatrics, National Hospital Organization, Saitama Hospital, 2-1 Suwa, Wako-shi, Saitama 351-0102, Japan.
  • Maeda N; Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan.
  • Narabayashi A; Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan.
  • Kamei A; Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan.
  • Shibata A; Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, 284-1 Yobe-cho, Ashikaga, Tochigi 326-0843, Japan.
  • Yamada G; Department of Pediatrics, Ota Memorial Hospital, 455-1 Ohshimacho, Ota City, Gunma 273-8585, Japan.
  • Nishida M; Department of Pediatrics, Shizuoka City Shimizu Hospital, 1231 Miyakami, Shimizu-ku, Shizuoka-shi, Shizuoka 424-8636, Japan.
  • Kenichiro T; Department of Pediatrics, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0062, Japan.
  • Chiga M; Department of Pediatrics, Tokyo Metropolitan Otsuka Hospital, 2-8-1 Minamiotsuka, Toshima-ku, Tokyo 170-8476, Japan.
  • Shimoyamada M; Department of Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-0911, Japan.
  • Yoshida M; Department of Pediatrics, Sano Kosei General Hospital, 1728 Horigome-chou, Sano-city, Tochigi 327-8511, Japan.
  • Fukushima N; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka, Kanagawa 254-0065, Japan.
  • Nakata Y; Department of Pediatrics, Nippon Koukan Hospital, 1-2-1 Koukan-dori, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0852, Japan.
  • Fukushima H; Department of Pediatrics, Tokyo Dental College Ichikawa General Hospital, 5-11-13, Sugano Ichikawa, Chiba 272-0824, Japan.
  • Kawakami C; National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
  • Narumi S; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
  • Sugaya N; Keio Pediatric Influenza Research Group, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Vaccine ; 42(23): 126241, 2024 Oct 03.
Article en En | MEDLINE | ID: mdl-39178768
ABSTRACT

BACKGROUND:

The annual administration of the influenza vaccine is the most effective method for preventing influenza. We have evaluated the effectiveness of the inactivated influenza vaccine in children aged 6 months to 15 years across the seasons from 2013/2014 to 2022/2023. This study aims to investigate the effectiveness of the inactivated influenza vaccine in the 2023/2024 season, the first year following the easing of strict COVID-19 measures, and possibly the last season when only the inactivated vaccine is available on the market.

METHODS:

Adjusted vaccine effectiveness for the 2023/2024 season was assessed using a test-negative case-control design, with results based on polymerase chain reaction and rapid influenza diagnostic tests. Vaccine effectiveness was calculated by influenza type and patient hospitalization/outpatient status.

RESULTS:

A total of 1832 children were recruited. The inactivated influenza vaccine was effective in preventing both symptomatic influenza A and B in both inpatient and outpatient settings. Overall vaccine effectiveness for influenza A was 51% (95% confidence interval [CI], 23%-69%, n = 930) in inpatient settings and 54% (95%CI, 27%-71%, n = 559) in outpatient settings. For influenza B, effectiveness was 60% (95%CI, 22%-79%, n = 859) in inpatient settings and 56% (95%CI, 26%-74%, n = 558) in outpatient settings. Analysis suggested that administering two doses enhanced effectiveness specifically against influenza B.

CONCLUSIONS:

This is the first study to demonstrate influenza vaccine effectiveness in children after the relaxation of strict COVID-19 measures in Japan (2023/2024). We recommend the current inactivated vaccine for preventing both influenza A and B in children, with consideration for the potential use of two doses to enhance effectiveness against influenza B.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Vacunas de Productos Inactivados / Gripe Humana / COVID-19 / Eficacia de las Vacunas Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Vacunas de Productos Inactivados / Gripe Humana / COVID-19 / Eficacia de las Vacunas Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos